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Easy Access to Antifungal Agents
Vulvovaginal candidiasis is a common problem; at one time or another most
women experience at least one episode of this bothersome condition. For the past
several years, the pharmaceutical industry has convinced women that this condi-
tion is easily treated and that they should recognize the symptoms of vulvovaginal
candidiasis. Thus women have had access to a variety of intravaginal antifungal
agents to treat this condition.
However, the symptoms can often be confusing; many physicians have diffi-
culty in making a correct diagnosis. One also wonders why so many antifungal
agents with a very similar spectrum of activity are available without a prescription.
The effectiveness of these agents is similar and, in fact, not very efficacious. Yet
women buy these products and spend millions of dollars without achieving suit-
able results. This is caused by one of three situations: the diagnosis is incorrect, the
diagnosis is correct but the organism is not C. albicans and is likely to be resistant,
or the organism is C. albicans but is not responsive to the agent.
The answer from the pharmaceutical industry and many of our colleagues is to
develop a rapid test that can be performed by the patient. This may be suited for
the individual who has an uncomplicated first episode and who does not have an
associated condition--but this is a rare individual.
Why is this happening? Why is there a movement to encourage self-diagnosis?
Perhaps physicians do not consider vaginitis a significant problem and do not learn
or take the time to evaluate the vaginal ecosystem correctly. As a result they cannot
make an accurate diagnosis leading to appropriate treatment.
Physicians must understand that the status of the vaginal ecosystem does affect
the well being of both pregnant and nonpregnant patients. Even a "single" yeast
infection in a pregnant patient can result in a significant problem, e.g., Candida
chorioamnionitis.
Our concern should be to ensure that the treatment is specific and that an
associated condition is not present that can place the patient in jeopardy of com-
promising her reproductive capabilities.
I believe that the infectious diseases societies must, once again, awaken our
colleagues and raise the level of awareness regarding infectious diseases. We need
to bring attention to all the conditions in the vaginal ecosystem that impact on
women’s health. This should be done not by rephrasing the same old song, but
bringing our specialty into the twenty-first century by making our scientific data
applicable to everyday clinical situations. Now is an opportune time for both
societies to step forward, to be proactive and to make recommendations, and to
work together to improve the health of women.
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